Table 4.
Results of the generalized estimating equation analyzing the effect of 2-year MMSE changes in patients with AD and MCI.
| Β | SE | 95% CI | P value | |
|---|---|---|---|---|
| Gender | ||||
| Male | −0.03 | 0.27 | (−0.56, 0.51) | 0.93 |
| Female | Ref | |||
| MCP-1 level | −1.75 | 0.88 | (−3.47, −0.03) | 0.046 |
| APOE ε4 | ||||
| non-carrier | 0.47 | 0.32 | (−0.16, 1.10) | 0.14 |
| carrier | Ref | |||
| Age | 0.04 | 0.02 | (−0.01, 0.08) | 0.12 |
| Years of education | −0.04 | 0.03 | (−0.10, 0.03) | 0.25 |
| Time | −1.19 | 0.14 | (−1.46, −0.92) | < 0.001 |
| Baseline MMSE | 0.96 | 0.03 | (0.91, 1.00) | < 0.001 |
| CCI | −0.22 | 0.16 | (−0.53, 0.10) | 0.19 |
Adjusted for age, years of education, gender, time, APOE ε4 carrier, and baseline MMSE.
MMSE, Mini-Mental Status Examination; AD, Alzheimer’s disease; MCI, mild cognitive impairment; MCP-1, Monocyte chemoattractant protein-1; APOE, apolipoprotein E; CCI, Charlson comorbidity index.